Session Information
Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: The Raynaud’s Condition Score (RCS) diary is a clinician-derived validated patient-reported outcome (PRO) instrument for assessing the frequency, duration and severity of Raynaud’s phenomenon in systemic sclerosis (SSc-RP).
Methods: The Scleroderma Clinical Trials Consortium Vascular Working Group (SCTC-VWG) has been assembled to develop better methods for assessing and managing peripheral vascular manifestations of SSc. SCTC-VWG members (n=28) were invited to participate in a survey gauging attitudes towards the RCS diary and the perceived need for novel tools for assessing SSc-RP.
Results: Nineteen SCTC-VWG members (68% response rate) completed the survey. All were practicing rheumatologists with an interest in SSc (79% treating >15 SSc patients per month) affiliated with academic units based in North America (n=9), Europe (n=8), South America (n=1) and Australasia (n=1). The majority of respondents (95%) had participated in clinical trials of SSc and most (83%) had experience of SSc-RP endpoints. There were mixed views from respondents regarding the extent to which the RCS diary captures its intended conceptual framework (Table). There was broad consensus that RCS diary returns could be influenced by seasonal variation in weather, efforts made by patients to avoid or ameliorate attacks of RP, habituation to RP symptoms, the potential evolution of RP symptom characteristics with progressive obliterative microangiopathy, patient coping strategies, respondent burden and placebo effect (Table). There was consensus that the RCS diary might be a barrier to drug development (79% of respondents agree/strongly agree), that a novel PRO instrument for SSc-RP might aid drug development for SSc-RP (95% agree/strongly agree) and that a novel PRO instrument for SSc-RP should be developed with the combined input of clinicians and patients (84% agree/strongly agree).
Conclusion: The chief limitations of this pilot work are the relatively small survey size and selection bias derived from targeting SCTC-VWG members. Nevertheless, the SCTC-VWG benefits from its composition of highly experienced clinicians affiliated with specialized SSc centers across four continents. A number of perceived limitations of the RCS diary have been highlighted along with concerns that these factors might impede drug development programs for SSc-RP. There is support within the scleroderma community for the development of a novel PRO instrument for SSc-RP. Table 1. Responses obtained from SCTC-VWG members in survey
Extent to which respondents agreed with each statement: | |||||||
Unable to offer opinion | Strongly disagree | Disagree | Neither disagree or agree | Agree | Strongly agree | ||
The RCS diary accurately reflects: | Frequency of RP attacks | 1 (5) | 1 (5) | 2 (11) | 6 (32) | 8 (42) | 1 (5) |
Duration of RP attacks | 1 (5) | 1 (5) | 3 (16) | 8 (42) | 5 (26) | 1 (5) | |
Overall severity and impact of RP | 1 (5) | 1 (5) | 2 (11) | 6 (32) | 7 (37) | 2 (11) | |
The RCS diary returns are influenced by: | Difficulty recognizing attacks of RP | 0 (0) | 0 (0) | 7 (37) | 2 (11) | 7 (37) | 3 (16) |
Seasonal variation in weather | 1 (5) | 0 (0) | 0 (0) | 0 (0) | 9 (47) | 9 (47) | |
Efforts made to avoid attacks of RP | 1 (5) | 0 (0) | 0 (0) | 3 (16) | 10 (53) | 5 (26) | |
Efforts made to ameliorate attacks of RP | 1 (5) | 0 (0) | 1 (5) | 3 (16) | 11 (58) | 3 (16) | |
Habituation to RP symptoms over time | 1 (5) | 0 (0) | 0 (0) | 0 (0) | 12 (63) | 6 (32) | |
Evolution of morphological digital microvascular disease | 1 (5) | 0 (0) | 1 (5) | 4 (21) | 9 (47) | 4 (21) | |
Patient coping strategies | 1 (5) | 0 (0) | 0 (0) | 1 (5) | 13 (69) | 4 (21) | |
Excessive respondent burden | 1 (5) | 0 (0) | 1 (5) | 2 (11) | 9 (47) | 6 (32) | |
Placebo effect | 2 (11) | 0 (0) | 1 (5) | 2 (11) | 8 (42) | 6 (32) | |
The RCS diary: | Might impede drug development in SSc-RP | 2 (11) | 0 (0) | 2 (11) | 0 (0) | 9 (47) | 6 (32) |
Is satisfactory and no further research is required in this area | 0 (0) | 7 (37) | 10 (53) | 1 (5) | 0 (0) | 1 (5) | |
A novel PRO instrument for SSc-RP: | Might aid drug development in SSc-RP | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 11 (58) | 7 (37) |
Should be primarily PATIENT-derived | 0 (0) | 0 (0) | 1 (5) | 3 (16) | 9 (47) | 6 (32) | |
Should be primarily CLINICIAN-derived | 0 (0) | 0 (0) | 9 (47) | 8 (42) | 2 (11) | 0 (0) | |
Should be CLINICIAN and PATIENT-derived | 0 (0) | 0 (0) | 1 (5) | 2 (11) | 7 (37) | 9 (47) |
To cite this abstract in AMA style:
Pauling J, Frech TM, Hughes M, Gordon JK, Domsic RT, Ingegnoli F, McHugh NJ, Johnson SR, Hudson M, Boin F, Ong V, Matucci Cerinic M, Altorok N, Scolnik M, Nikpour M, Shah A, Pope JE, Khanna D, Herrick AL. Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud’s Phenomenon in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/attitudes-toward-patient-reported-outcome-instruments-for-the-assessment-of-raynauds-phenomenon-in-systemic-sclerosis/. Accessed .« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/attitudes-toward-patient-reported-outcome-instruments-for-the-assessment-of-raynauds-phenomenon-in-systemic-sclerosis/